2-(isopropylamino)-2-methylpropan-1-ol | 90434-44-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(isopropylamino)-2-methylpropan-1-ol
• 英文别名: 2-Methyl-2-(propan-2-ylamino)propan-1-ol
• CAS: 90434-44-9
• 化学式: C₇H₁₇NO
• mdl: MFCD11163992
• 分子量: 131.218
• InChiKey: WZSRNAWJDQGJEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(isopropylamino)-2-methylpropan-1-ol 在 甲酸 、 三(五氟苯基)硼烷 、 2,6-bis((S)-4-(3-chlorophenyl)-4,5-dihydrooxazol-2-yl)pyridine 、 水 、 双氧水 、 三乙胺 、 magnesium triflate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 38.0h， 生成
  参考文献：
  名称：

  通过手性和非手性路易斯酸催化剂的协同作用，通过烯烃衍生的亲核试剂对胺进行 C-H 官能化：在对映选择性合成中的应用

  摘要：

  已经开发了 α-氨基 CH 键的催化转化，以提供有价值的对映体富集的 α-取代胺，这些实体在药物和生物活性天然产品中很普遍。通常，此类过程在氧化条件下进行并且需要贵金属基催化剂。在这里，我们公开了 N-烷基胺和 α,β-不饱和化合物的对映选择性结合的策略，在氧化还原中性条件下进行，并通过看似有竞争力的路易斯酸、B(C6F5)3 和手性镁的协同作用促进-PyBOX 复合体。因此，通过原位生成的对映体富集的镁烯醇化物和合适的亲电子试剂的立体选择性反应，可以合成多种 β-氨基羰基化合物，具有完全的原子经济性。

  DOI：

  10.1021/jacs.8b06699
• 作为产物：
  描述：

  bi(5,5-dimethyl-4-ethyl-2-oxomorpholin-3-yl) 在 氧气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以40%的产率得到2-(isopropylamino)-2-methylpropan-1-ol
  参考文献：
  名称：

  N-Alkyl-5,5-dimethyl-2-oxomorpholin-3-yl radicals. Characterization and reaction with molecular oxygen

  摘要：

  The synthesis of bi(4,5,5-trimethyl-2-oxomorpholin-3-yl) (TM-3' dimer), bi(5,5-dimethyl-4-ethyl-2-oxomorpholin-3-yl) (DEM-3 dimer), and bi(5,5-dimethyl-4-isopropyl-2-oxomorpholin-3-yl) (DIM-3 dimer) by one-electron oxidation of 4,5,5-trimethyl-2-oxomorpholine (8), 5,5-dimethyl-4-ethyl-2-oxomorpholine (9), and 5,5-dimethyl-4-isopropyl-2-oxomorpholine (10), respectively, with photochemically generated tert-butoxyl radical is described. dl-TM-3' dimer, meso-DEM-3 dimer, and meso-DIM-3 dimer were characterized from spectra and by X-ray crystallography. In solution the radical dimers existed in equilibrium with the captodatively substituted radicals, 4,5,5-trimethyl-2-oxomorpholin-3-yl (TM-3'), 5,5-dimethyl-4-ethyl-2-oxomorpholin-3-yl (DEM-3), and 5,5-dimethyl-4-isopropyl-2-oxomorpholin-3-yl (DIM-3), respectively, as indicated by EPR spectroscopy. The activation parameters for bond homolysis in ethanol solvent were measured by oxidatively trapping the radicals with diphenylpicrylhydrazyl (DPPH). The half-lives for bond homolysis vary by 5 orders of magnitude at 25-degrees-C with a value of only 2.3's for DIM-3 dimer. DIM-3 dimer reacted quantitatively with molecular oxygen to form a mixture of meso- and dl-bis(5,5-dimethyl-4-isopropyl-2-oxomorpholin-3-yl) peroxides (DIM-3 peroxides), which were isolated and characterized spectroscopically and analytically. At ambient temperature the peroxides fragmented by C-O bond homolysis to release the DIM-3 radical as indicated by EPR spectroscopy and were solvolyzed by protic solvent with release of hydrogen peroxide. The solvolysis was reversed by evaporation of the protic solvent, which restored most of the DIM-3 peroxides. The peroxides also slowly fragmented irreversibly to 5,5-dimethyl-3-hydroxy-4-isopropyl-2-oxomorpholine (21) and 5,5-dimethyl-2, 3-dioxo-4-isopropylmorpholine (23) in polar aprotic solvent.

  DOI：

  10.1021/ja00023a040

文献信息

• [EN] CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE CONDENSÉS, SUBSTITUÉS PAR DES GROUPES HYDROXY TERTIAIRES, UTILISÉS COMME INHIBITEURS DE PI3K-GAMMA
  申请人：INCYTE CORP

  公开号：WO2019079469A1

  公开（公告）日：2019-04-25

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-y which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  这种应用涉及到式(I)的化合物或其药用可接受的盐，这些化合物是PI3K-y的抑制剂，对于治疗自身免疫疾病、癌症、心血管疾病和神经退行性疾病等疾病是有用的。
• DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
  申请人：PFIZER INC.

  公开号：US20150259323A1

  公开（公告）日：2015-09-17

  Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

  本文描述了抑制二酰基甘油酰基转移酶2（DGAT2）活性的化合物I的使用，以及它们在治疗相关动物疾病中的用途。
• [EN] BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] DÉRIVÉ DE BENZYLAMINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 苄胺类衍生物及其制备方法与用途
  申请人：ACAD OF MILITARY MEDICAL SCIENCES

  公开号：WO2022033303A1

  公开（公告）日：2022-02-17

  涉及苄胺类衍生物及其制备方法与用途。具体涉及通式(Ⅰ)所示的苄胺类衍生物，或其药学上可接受的立体异构体、盐、溶剂化物或前药，其与人PD-L1有很强的结合能力，能明显抑制PD-1/PD-L1相互作用，具有显著地体内抗肿瘤药效。因此，还涉及所述苄胺类衍生物的制备方法及其在制备治疗与PD-1/PD-L1相关疾病的药物中的用途，
• Transfer Hydrogenation of Cyclopamine Analogs
  申请人：Genov Daniel G.

  公开号：US20120065399A1

  公开（公告）日：2012-03-15

  Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.

  本文提供了一种用于将似jervine型Veratrum生物碱的酮类似物（如环毒素）进行转移氢化的方法。本文还提供了新型的钌转移氢化催化剂。
• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。